Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate progression free survival primarily. The secondary
objectives are to evaluate the antitumor activity, as assessed by objective tumor response,
duration of clinical benefit, overall survival, and the safety profile of TAS-109